Word: within
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...important to clarify for your readers that not all those who receive a diagnosis of myelodysplastic syndrome (MDS) will die within two years of getting it, regardless of whether they take "conventional blood medications" or azacitidine. Of the estimated 60,000 people living with MDS in the U.S., 75% have a lower-risk diagnosis, providing a much less ominous prognosis. Research indicates that lower-risk MDS patients under age 70 survive, on average, four to nine years after diagnosis, meaning that some MDS patients live much longer. Richard M. Stone, Mikkael A. Sekeres, Aplastic Anemia & MDS International Foundation, ROCKVILLE...
...important to clarify for your readers that not all those who receive a diagnosis of myelodysplastic syndrome (MDS) will die within two years of getting it, regardless of whether they take "conventional blood medications" or azacitidine. Of the estimated 60,000 people living with MDS in the U.S., 75% have a lower-risk diagnosis, providing a much less ominous prognosis. Research indicates that lower-risk MDS patients under age 70 survive, on average, four to nine years after diagnosis, meaning that some MDS patients live much longer. Richard M. Stone, Mikkael A. Sekeres, Aplastic Anemia & MDS International Foundation Rockville...
...finches changed depending on environmental conditions. Darwin explained this by natural selection. Other scientists have noticed that the bill lengths of those finches return to normal when conditions return to normal. Sounds like epigenetics and not Darwinian evolution. Darwin skeptics tend to agree that organisms can adapt (or evolve) within certain boundaries, but such organisms do not evolve into new species. Bygren's study of epigenetics would seem to explain this phenomenon better and more simply than Darwinian evolution. Timothy Cox Palm Beach Gardens...
...that Dave deBronkart learned he had Stage 4 kidney cancer, his doctor handed him a prescription slip. On it, he'd scribbled ACOR.org. Within 11 minutes of submitting his first post to the Association of Cancer Online Resources, deBronkart, a software marketer in Nashua, N.H., received recommendations for top specialists - with links included - from patients on the site's kidney-cancer list. Within half an hour, an e-mail arrived from an ACOR member suggesting which scans might be appropriate and offering details about interleukin-2, the only treatment at the time that resembled a cure. "This is scary, terrifying...
...following text appears within a chart. Please see hardcopy or PDF for actual chart...